Sugi Predict

Sugi Predict / Compounds / SCHEMBL3273665

SCHEMBL3273665

SCHEMBL3273665

COc1cc(-c2noc(C)n2)ccc1C(=O)NC(C)c1nc(-c2ccncn2)cc(=O)n1C

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ GSK3B P49841 10/20 0.39
▸ ROCK1 Q13464 5/20 0.39
▸ MAPK1 P28482 3/20 0.39
▸ CYP2D6 P10635 3/20 0.39
▸ ROCK2 O75116 3/20 0.39
▸ PRKCG P05129 2/20 0.39
▸ PRKACA P17612 2/20 0.39
▸ RPS6KB1 P23443 2/20 0.39
▸ GSK3A P49840 2/20 0.39
▸ PRKX P51817 2/20 0.39
▸ PRKCD Q05655 2/20 0.39
▸ PRKG1 Q13976 2/20 0.39
▸ PKN2 Q16513 2/20 0.39
▸ CLK4 Q9HAZ1 2/20 0.39
▸ SGK2 Q9HBY8 2/20 0.39
▸ CYP3A4 P08684 1/20 0.39
▸ CYP2C9 P11712 1/20 0.39
▸ KCNT1 Q5JUK3 1/20 0.38
▸ CYP1A2 P05177 2/20 0.37
▸ LMNA P02545 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3273844 0.85 MAPT (0.44) GSK3BMAPK1CYP2D6CYP1A2LMNA
SCHEMBL3273841 0.84 ROCK1 (0.40) GSK3BROCK1MAPK1CYP2D6ROCK2
SCHEMBL3275123 0.84 GSK3B (0.44) GSK3BROCK1MAPK1CYP2D6ROCK2
SCHEMBL3274484 0.83 GSK3B (0.41) GSK3BROCK1CYP2D6ROCK2CYP3A4
SCHEMBL3274773 0.83 GSK3B (0.52) GSK3BROCK1CYP2D6ROCK2CYP1A2
SCHEMBL3273802 0.83 TP53 (0.40) GSK3B
SCHEMBL3273980 0.81 GSK3B (0.41) GSK3BROCK1MAPK1CYP2D6ROCK2
SCHEMBL3641579 0.79 MAPT (0.39) GSK3BLMNA
SCHEMBL3273383 0.78 GSK3B (0.41) GSK3BROCK1MAPK1CYP2D6ROCK2
SCHEMBL3273631 0.78 HTR4 (0.41) GSK3BCYP2D6CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8592436-B2 Arylamide pyrimidone derivatives SANOFI (FR) 2013-11-26 — — US claimed
US-20100087460-A1 ARYLAMIDE PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2010-04-08 — — US claimed
EP-2148866-A2 ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES Sanofi-Aventis (FR) 2010-02-03 — — EP claimed
WO-2008155669-A2 ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI-AVENTIS (FR) 2008-12-24 — — WO claimed
EP-1992620-A1 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases Sanofi-Aventis (FR) 2008-11-19 — — EP claimed
US-8592436-B2 Arylamide pyrimidone derivatives SANOFI (FR) 2013-11-26 — — US disclosed
EP-2148866-B1 ARYLAMIDE PYRIMIDONE DERIVATIVES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES SANOFI SA (FR) 2013-07-17 — — EP disclosed
US-20100087460-A1 ARYLAMIDE PYRIMIDONE DERIVATIVES SANOFI-AVENTIS (FR) 2010-04-08 — — US disclosed
EP-1992620-A1 Arylamide pyrimidone derivatives for the treatment of neurodegenerative diseases Sanofi-Aventis (FR) 2008-11-19 — — EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100087460-A1 ARYLAMIDE PYRIMIDONE DERIVATIVES DHFR, XDH, HPRT1 GSK3B 3247/4885ROCK1 2302/4885MAPK1 1407/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.